This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alan C. Bird, MD

Arch Ophthalmol. 1997;115(10):1311-1313.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

AGE-RELATED MACULAR disease (AMD) accounts for approximately 50% of all cases of registered blindness in England and Wales¹; this high prevalence is likely to exist in all economically developed white communities.^2-4 A recent analysis indicates that the prevalence seems to be increasing at a rate not fully explained by the increasing age of the population⁵; as a cause of visual loss, AMD is as common as diabetes and glaucoma during working life.⁵ Despite the early expectations,^6-8 it is evident that the techniques of laser treatment will not have a major effect on blindness due to AMD.^9-11 Other forms of treatment are under trial,^12-18 but they may not be vastly more successful than photocoagulation. This requires that our knowledge of the behavior and pathogenesis of the disorder be reexamined in the hope that alternative approaches to management be identified.

There is good evidence of . . . [Full Text PDF of this Article]

Author Affiliations
London, England

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?